IC
VKTX icon

Ikarian Capital’s Viking Therapeutics VKTX Stock Holding History

Ikarian Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$16.4M – 155
2024
Q1 		$16.4M Buy
+200,000
New +$8.9M 1.8% 15
2020
Q1 		– Sell
-150,000
Closed -$1.2M – 174
2019
Q4 		$1.2M Buy
+150,000
New +$1.09M 0.19% 76

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ikarian Capital's VKTX Position: Q2 2026 in Review

Ikarian Capital held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 9,717 shares worth $379K. The position accounts for 0.04% of the portfolio, ranked #132.

Ikarian Capital first reported a position in VKTX in Q4 2019 and has held it in 19 quarters since. The position peaked at $7.33M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ikarian Capital held 9,717 shares of Viking Therapeutics worth $379K as of Q2 2026.
  • Ikarian Capital left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.04% of Ikarian Capital's portfolio in Q2 2026, its #132 holding.
  • Ikarian Capital first reported a position in Viking Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • Ikarian Capital's Viking Therapeutics position peaked at $7.33M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.